Zaid Harras B, Yang David Y, Tollefson Matthew K, Frank Igor, Winters Jeffrey L, Thapa Prabin, Parker William P, Thompson R Houston, Karnes R Jeffrey, Boorjian Stephen A
Department of Urology, Mayo Clinic, Rochester, MN.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Urology. 2016 Jun;92:57-62. doi: 10.1016/j.urology.2016.02.044. Epub 2016 Mar 8.
To evaluate the safety and efficacy of intraoperative tranexamic acid (TA), an antifibrinolytic, in reducing perioperative blood transfusion (PBT) for patients undergoing open radical cystectomy (RC) for bladder cancer.
We instituted a change in our institutional clinical practice starting in April 2013, whereby all patients undergoing open RC were administered intraoperative intravenous TA. Patients with a history of venous thromboembolism (VTE) or coronary stent insertion within the year prior to RC did not receive TA. Receipt of a PBT, defined as transfusion of red blood cells during RC or within the postoperative hospitalization, and VTE within 30 days of RC were recorded and compared with a matched cohort of patients treated with RC at our center prior to the initiation of TA utilization.
A total of 103 patients received TA during open RC between April 2013 and July 2015. These patients were matched 1:2 to historic controls. We found that TA infusion was associated with a significantly decreased rate of PBT, as 32 of 103 (31.1%) patients treated with TA received a PBT, versus 115 of 200 (57.7%) matched controls (P < .0001). Importantly, TA did not significantly increase the rate of perioperative VTE, as 5 patients (4.9%) who received TA were diagnosed with a VTE within 30 days of RC, compared with 6 (3.0%) of the matched controls (P = .52).
We noted that the use of intraoperative TA during open RC was associated with a significant reduction in PBT, and did not significantly increase perioperative VTE risk.
评估抗纤溶药物氨甲环酸(TA)在降低膀胱癌根治性膀胱切除术(RC)患者围手术期输血(PBT)方面的安全性和有效性。
自2013年4月起,我们对机构临床实践进行了一项改变,即所有接受开放性RC的患者术中静脉注射TA。RC术前一年内有静脉血栓栓塞(VTE)病史或冠状动脉支架植入史的患者不接受TA。记录RC期间或术后住院期间接受PBT(定义为输注红细胞)的情况以及RC后30天内发生VTE的情况,并与我们中心在开始使用TA之前接受RC治疗的匹配队列患者进行比较。
2013年4月至2015年7月期间,共有103例患者在开放性RC术中接受了TA。这些患者与历史对照组按1:2匹配。我们发现TA输注与PBT发生率显著降低相关,接受TA治疗的103例患者中有32例(31.1%)接受了PBT,而匹配对照组的200例中有115例(57.7%)(P < 0.0001)。重要的是,TA并未显著增加围手术期VTE发生率,接受TA治疗的5例患者(4.9%)在RC后30天内被诊断为VTE,而匹配对照组为6例(3.0%)(P = 0.52)。
我们注意到,在开放性RC术中使用TA与PBT显著减少相关,且未显著增加围手术期VTE风险。